Intermittent Preventive Treatment With Antimalarials in Kenyan Infants

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centers for Disease Control and Prevention
• Collaborators: Bill and Melinda Gates Foundation; Kenya Medical Research Institute
• Treatments: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Chlorproguanil; Dapsone; Fanasil, pyrimethamine drug combination; Proguanil; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• Presenting for Pentavalent 1 immunization

• Age 5 weeks to 16 weeks

• Parent or guardian currently resident in study catchment area

• Parent or guardian has given permission for their child to participate

Exclusion Criteria:

• Known allergy to any of the study drugs

• Current Cotrimoxazole prophylaxis

• Concomitant disease requiring hospitalization or transfusion

• Plans to be away from the study area for more than 6 months during the next year